China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for HS-20117, a bispecific antibody (BsAb) targeting both EGFR and cMet in advanced solid tumors.
Strategic Licensing Deal with Biotheus
In a significant move to expand its pipeline, Hansoh struck a licensing deal worth RMB 1.468 billion with compatriot firm Biotheus in November 2022. This deal granted Hansoh the development and commercialization rights to HS-20117 in China, including Hong Kong, Macau, and Taiwan. The collaboration aims to leverage the potential of HS-20117 in treating patients with advanced solid tumors, offering a new therapeutic option for those with EGFR and cMet-driven diseases.
HS-20117: A Promising Approach to Solid Tumor Treatment
HS-20117’s dual targeting mechanism of action offers a unique approach to cancer treatment, potentially enhancing the efficacy of therapies for patients with advanced solid tumors. The bispecific antibody’s ability to target both EGFR and cMet pathways positions it as a promising candidate in the field of oncology, where innovative treatments are crucial for improving patient outcomes.-Fineline Info & Tech
